Estimation of the Stage-Wise Costs of Breast Cancer in Germany Using a Modeling Approach

• DOI: 10.20944/preprints202207.0140.v1
• Publication Date: 2022-07-08T08:54:14Z
• Authors: Khan Shah Alam; Karla Hernandez-V...; Diego Andres Hern...; Schlander Michael
• Keywords: stage-wise costs; Cost-Benefit Analysis; review; direct medical costs; modeling; Breast Neoplasms; Health Care Costs; 3. Good health; medicine_pharmacology_other; 03 medical and health sciences; breast cancer; 0302 clinical medicine; Germany; stage-specific costs; Humans; Female; Public Health; Public aspects of medicine; RA1-1270; Delivery of Health Care

Breast cancer (BC) is a heterogeneous disease representing substantial economic burden. In order to develop policies that successfully decrease this burden, the factors affecting costs need be fully understood. Evidence suggests early detection in Stage I has lower cost than late detection. We aim provide conservative estimates of BC's stage-wise medical from German healthcare and payer's perspective. To end, we conducted literature review articles evaluating BC Germany through PubMed, Web Science, Econ Lit databases supplemented by Google Scholar. developed decision tree model estimate related using available treatment information. The generated seven studies; none estimated BC. studies were classified into two groups: (1) case scenarios (five studies) based on administrative data. first sickness funds data study (Gruber, Stock, et al. 2012) used 1999 information approach attributable cost; their results suggest range between €3,929 €11,787 depending age. second (Kreis, Plöthner, 2020) 2011-2014 suggested an initial phase incremental €21,499, intermediate €2,620, terminal €34,513 per incident case. Our €21,523 for I, €25,679 II, €30,156 III, €42,086 IV. Alternatively, modeled are €20,284 care, €851 €34,963 care. phases care consistent with recent provided Kreis Plöthner Furthermore, collected primarily reimbursement purposes, where ICD-10 classification system defines diagnosis. As result, claims lack clinical necessary understand costs. model-based fill gap inform future evaluations interventions.